Recon: FDA approves Apellis’ eye disorder drug Syfovre; Pfizer pulls participants from Lyme disease trial over GCP issues
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy